Skip to Content
Merck
All Photos(1)

Documents

O0391

Sigma-Aldrich

Olopatadine hydrochloride

≥98% (HPLC)

Synonym(s):

(11Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride, AL-4943A, KW-4679, Opatanol, Patanol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H23NO3·HCl
CAS Number:
140462-76-6
Molecular Weight:
373.87
MDL number:
MFCD00875716
UNSPSC Code:
12352200
PubChem Substance ID:
329818840
NACRES:
NA.77

Assay

≥98% (HPLC)

form

solid

solubility

H2O: ≥20 mg/mL

storage temp.

room temp

SMILES string

Cl.CN(C)CC\C=C1\c2ccccc2COc3ccc(CC(O)=O)cc13

InChI

1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;

InChI key

HVRLZEKDTUEKQH-NOILCQHBSA-N

Gene Information

human ... HRH1(3269)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Olopatadine is a histamine H1 receptor antagonist and mast cell stabilizer. The low level of occupancy H1 receptors in the brain explains the low sedation effect of olopatidine. It is believed that olopatidine is a substrate for P-glycoprotein, which limits its brain penetration.

Pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

Signal Word

Danger

Hazard Statements

H301,H400

Precautionary Statements

P273 - P301 + P310 + P330

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yukari Okubo et al.
The Journal of dermatological treatment, 24(2), 153-160 (2011-08-04)
An increased dose of the prescribed drug or a change of the drug is recommended in the treatment for the patients with urticaria refractory to the standard dose of antihistamines. Efficacy and safety of doubling the dose of cetirizine were
Masahiko Shimura et al.
American journal of ophthalmology, 151(4), 697-702 (2011-01-25)
To evaluate the effectiveness of pre-seasonal treatment with topical olopatadine on the reduction of clinical symptoms of seasonal allergic conjunctivitis (SAC). Prospective interventional case series. Eleven patients with SAC received topical olopatadine in one eye at least two weeks before
Santa J Ono et al.
Drug design, development and therapy, 5, 77-84 (2011-02-23)
Antihistamines constitute the first line of therapy for allergic conjunctivitis, and are safe and effective in relieving the signs and symptoms of ocular allergy. Despite this, they are less effective than some other drugs in relieving delayed symptoms of allergic
Hiroyuki Kamei et al.
Archives of dermatological research, 304(4), 263-272 (2011-12-02)
Since most first-generation antihistamines have undesirable sedative effects on the central nervous systems (CNS), newer (second-generation) antihistamines have been developed to improve patients' quality of life. However, there are few reports that directly compare the antihistaminic efficacy and impairment of
Eli O Meltzer et al.
Allergy and asthma proceedings, 32(3), 213-220 (2011-04-12)
Allergic rhinitis (AR) is highly prevalent in children. Olopatadine, 0.6% nasal spray (olopatadine) is approved for the relief of seasonal allergic rhinitis (SAR) symptoms in children 6 years of age and older. The objective of this study is to provide
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service